Muscle atrophy

Revision as of 17:34, 9 August 2012 by WikiBot (talk | contribs) (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Muscle atrophy
Muscle atrophy.
Image courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology

WikiDoc Resources for Muscle atrophy

Articles

Most recent articles on Muscle atrophy

Most cited articles on Muscle atrophy

Review articles on Muscle atrophy

Articles on Muscle atrophy in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Muscle atrophy

Images of Muscle atrophy

Photos of Muscle atrophy

Podcasts & MP3s on Muscle atrophy

Videos on Muscle atrophy

Evidence Based Medicine

Cochrane Collaboration on Muscle atrophy

Bandolier on Muscle atrophy

TRIP on Muscle atrophy

Clinical Trials

Ongoing Trials on Muscle atrophy at Clinical Trials.gov

Trial results on Muscle atrophy

Clinical Trials on Muscle atrophy at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Muscle atrophy

NICE Guidance on Muscle atrophy

NHS PRODIGY Guidance

FDA on Muscle atrophy

CDC on Muscle atrophy

Books

Books on Muscle atrophy

News

Muscle atrophy in the news

Be alerted to news on Muscle atrophy

News trends on Muscle atrophy

Commentary

Blogs on Muscle atrophy

Definitions

Definitions of Muscle atrophy

Patient Resources / Community

Patient resources on Muscle atrophy

Discussion groups on Muscle atrophy

Patient Handouts on Muscle atrophy

Directions to Hospitals Treating Muscle atrophy

Risk calculators and risk factors for Muscle atrophy

Healthcare Provider Resources

Symptoms of Muscle atrophy

Causes & Risk Factors for Muscle atrophy

Diagnostic studies for Muscle atrophy

Treatment of Muscle atrophy

Continuing Medical Education (CME)

CME Programs on Muscle atrophy

International

Muscle atrophy en Espanol

Muscle atrophy en Francais

Business

Muscle atrophy in the Marketplace

Patents on Muscle atrophy

Experimental / Informatics

List of terms related to Muscle atrophy

Template:AB


Muscle atrophy refers to a decrease in the size of skeletal muscle, which occurs in a variety of settings. Atrophy may or may not be distinct from "sarcopenia", which is the loss of muscle seen in the aged.

When a muscle atrophies, it necessarily becomes weaker, since the ability to exert force is related to mass.

Clinical settings of atrophy

There are many diseases and conditions which cause a decrease in muscle mass, known as atrophy, including: inactivity, as seen when a cast is put on a limb, or upon extended bedrest (which can occur during a prolonged illness); cachexia - which is a "body-wasting" syndrome that is a co-morbidity of cancer and Congestive Heart Failure; Chronic Obstructive Pulmonary Disease; burns, liver failure, etc. Other syndromes or conditions which can induce skeletal muscle atrophy are congestive heart disease, liver disease, and starvation.

Other muscles diseases, distinct from atrophy

During aging, there is a gradual decrease in the ability to maintain skeletal muscle function and mass. This condition is called "sarcopenia". The exact cause of sarcopenia is unknown, but it may be due to a combination of the gradual failure in the "satellite cells" which help to regenerate skeletal muscle fibers, and a decrease in sensitivity to or the availability of critical secreted growth factors which are necessary to maintain muscle mass and satellite cell survival.

In addition to the simple loss of muscle mass (atrophy), or the age-related decrease in muscle function (sarcopenia), there are other diseases which may be caused by structural defects in the muscle (muscular dystrophy), or by inflammatory reactions in the body directed against muscle (the myopathies).

Pathophysiology

Muscle atrophy occurs by a change in the normal balance between protein synthesis and protein degradation. During atrophy, there is a down-regulation of protein synthesis pathways, and an activation of protein breakdown pathways. The particular protein degradation pathway which seems to be responsible for much of the muscle loss seen in a muscle undergoing atrophy is the "ATP-dependent, ubiquitin/proteasome pathway. In this system, particular proteins are targeted for destruction by the ligation of at least four copies of a small peptide called ubiquitin onto a substrate protein. When a substrate is thus "poly-ubiquitinated", it is targeted for destruction by the proteasome. Particular enzymes in the ubiquitin/proteasome pathway allow ubiquitination to be directed to some proteins but not others - specificity is gained by coupling targeted proteins to an "E3 ubiquitin ligase". Each E3 ubiquitin ligase binds to a particular set of substrates, causing their ubiquitination.

Diagnostic Findings

Potential treatment

Muscle atrophy can be opposed by the signaling pathways which induce muscle hypertrophy, or an increase in muscle size. Therefore one way in which exercise induces an increase in muscle mass is to downregulate the pathways which have the opposite effect.

See also

External links

Template:WH Template:WS